Coronavirus: "we have already had to stop treatment" of hydroxychloroquine-azithromycin at the CHU in Nice

Professor Émile Ferrari heads the cardiology department at the Pasteur hospital in Nice. He discussed the hydroxychloroquine-azithromycin treatment in relation to severe forms of Covid-19. The CHU in Nice, like other medical establishments, is testing the hydroxychloroquine-azithromycin combination in patients hospitalized with severe forms of Covid-19. How are these patients tracked from a cardiological point of view? 'We have implemented a 7/7 and H24 monitoring method; all the Covid units of Nice University Hospital send us the patient's ECG [electrocardiogram, ed] recordings. We interpret them live and report anomalies which indicate a predisposition to toxicity. And which then require a cessation of treatment.' Has this ever happened? 'Yes, from the start of the trial. Thanks to this ECG follow-up, we highlighted the major risks of a very serious accident in a patient, and the treatment was immediately stopped.'